JP2015522815A - 乳癌の治療用ベバシズマブ併用療法の血漿バイオマーカー - Google Patents

乳癌の治療用ベバシズマブ併用療法の血漿バイオマーカー Download PDF

Info

Publication number
JP2015522815A
JP2015522815A JP2015519012A JP2015519012A JP2015522815A JP 2015522815 A JP2015522815 A JP 2015522815A JP 2015519012 A JP2015519012 A JP 2015519012A JP 2015519012 A JP2015519012 A JP 2015519012A JP 2015522815 A JP2015522815 A JP 2015522815A
Authority
JP
Japan
Prior art keywords
patient
vegf
biomarker
expression level
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015519012A
Other languages
English (en)
Japanese (ja)
Inventor
ウルズラ クロイゼ，
ウルズラ クロイゼ，
ニコラ ムーア，
ニコラ ムーア，
セリーヌ パロー，
セリーヌ パロー，
シュテファン シェラー，
シュテファン シェラー，
ノルベルト ヴィルト，
ノルベルト ヴィルト，
Original Assignee
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト filed Critical エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト
Publication of JP2015522815A publication Critical patent/JP2015522815A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015519012A 2012-06-26 2013-06-24 乳癌の治療用ベバシズマブ併用療法の血漿バイオマーカー Pending JP2015522815A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261664612P 2012-06-26 2012-06-26
US61/664,612 2012-06-26
US201261697667P 2012-09-06 2012-09-06
US61/697,667 2012-09-06
PCT/EP2013/063094 WO2014001232A1 (en) 2012-06-26 2013-06-24 Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer

Publications (1)

Publication Number Publication Date
JP2015522815A true JP2015522815A (ja) 2015-08-06

Family

ID=48672633

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015519012A Pending JP2015522815A (ja) 2012-06-26 2013-06-24 乳癌の治療用ベバシズマブ併用療法の血漿バイオマーカー

Country Status (10)

Country Link
EP (1) EP2864788A1 (xx)
JP (1) JP2015522815A (xx)
KR (1) KR20150024342A (xx)
CN (1) CN104364655A (xx)
BR (1) BR112014032456A2 (xx)
CA (1) CA2871385A1 (xx)
HK (1) HK1202334A1 (xx)
MX (1) MX2014014821A (xx)
RU (1) RU2015102026A (xx)
WO (1) WO2014001232A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3594365A4 (en) * 2017-03-08 2021-01-06 Industry - University Cooperation Foundation Hanyang University HER2-POSITIVE CANCER BIOMARKER AND ANTI-HER2 TREATMENT AND ITS USE
KR102028703B1 (ko) * 2017-11-21 2019-10-04 한양대학교 산학협력단 유방암의 진단 및 치료를 위한 바이오 마커

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006232A1 (en) * 2008-07-11 2010-01-14 Genentech, Inc. Methods and compositions for diagnostic use for tumor treatment
WO2011088149A2 (en) * 2010-01-12 2011-07-21 Prometheus Laboratories Inc. Methods for predicting response of triple-negative breast cancer to therapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0491675A1 (en) 1984-01-30 1992-06-24 Imperial Cancer Research Technology Limited Improvements relating to growth factors
US5401638A (en) 1986-06-04 1995-03-28 Oncogene Science, Inc. Detection and quantification of neu related proteins in the biological fluids of humans
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5081034A (en) 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
EP0494135B1 (en) 1989-09-29 1996-04-10 Oncogene Science, Inc. Human "neu" related protein p100 and use of the same for detecting preneoplastic or neoplastic cells in a human
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
US5994071A (en) 1997-04-04 1999-11-30 Albany Medical College Assessment of prostate cancer
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
DE19806989A1 (de) 1998-02-19 1999-08-26 Roche Diagnostics Gmbh Erzeugung räumlich scharf begrenzter Festphasen für Bindungsassays
US6833349B2 (en) * 1999-06-08 2004-12-21 Regeneron Pharmaceuticals, Inc. Methods of treating inflammatory skin diseases
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
DE102004029909A1 (de) 2004-06-21 2006-01-19 Roche Diagnostics Gmbh Verfahren und Vorrichtung zur Herstellung von bindungsfähigen Reagenzträgern
WO2009061800A2 (en) * 2007-11-09 2009-05-14 Genentech, Inc. Methods and compositions for diagnostic use in cancer patients
CN102099684A (zh) * 2008-02-29 2011-06-15 国立大学法人信州大学 前哨淋巴结内转移癌细胞检测试剂盒
BRPI0812682A2 (pt) 2008-06-16 2010-06-22 Genentech Inc tratamento de cáncer de mama metastático
AU2010273585B2 (en) * 2009-07-13 2015-04-23 Genentech, Inc. Diagnostic methods and compositions for treatment of cancer
MX2012001716A (es) * 2009-08-14 2012-04-02 Genentech Inc Marcadores biologicos para monitorizar la respuesta del paciente a los antagonistas vegf.
KR20130055647A (ko) * 2010-07-19 2013-05-28 에프. 호프만-라 로슈 아게 항암요법에 반응할 가능성이 증가된 환자를 확인하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010006232A1 (en) * 2008-07-11 2010-01-14 Genentech, Inc. Methods and compositions for diagnostic use for tumor treatment
WO2011088149A2 (en) * 2010-01-12 2011-07-21 Prometheus Laboratories Inc. Methods for predicting response of triple-negative breast cancer to therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RAMASWAMY ET AL.: "Phase II Trial of Bevacizumab in Combination with Weekly Docetaxel in Metastatic Breast Cancer Patie", CLINICAL CANCER RESEARCH, vol. 12, no. 10, JPN6017014414, 2006, pages 3124 - 3129, XP002604979, DOI: doi:10.1158/1078-0432.CCR-05-2603 *

Also Published As

Publication number Publication date
HK1202334A1 (en) 2015-09-25
WO2014001232A1 (en) 2014-01-03
MX2014014821A (es) 2015-02-12
CA2871385A1 (en) 2014-01-03
RU2015102026A (ru) 2016-08-10
BR112014032456A2 (pt) 2017-06-27
CN104364655A (zh) 2015-02-18
EP2864788A1 (en) 2015-04-29
KR20150024342A (ko) 2015-03-06

Similar Documents

Publication Publication Date Title
JP6664323B2 (ja) 神経膠芽腫を治療するための診断方法及び組成物
JP6057718B2 (ja) ベバシズマブ併用治療のための腫瘍組織に基づくバイオマーカー
JP6055764B2 (ja) 乳癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
US20140341893A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
JP2016014670A (ja) 抗癌治療への応答可能性の増大した患者を同定する方法
JP5963005B2 (ja) 膵臓癌の治療のためのベバシズマブ組合せ療法のための血漿バイオマーカー
JP2016014671A (ja) 抗癌治療への応答可能性の増大した患者を同定する方法
JP2015522815A (ja) 乳癌の治療用ベバシズマブ併用療法の血漿バイオマーカー
US20150352204A1 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
NZ624444B2 (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer
AU2016247169A1 (en) Tumor tissue based biomarkers for bevacizumab combination therapies

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160620

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20170414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170425

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20171121